Morphasol 4 mg/ml solution for injection for dogs and cats

Land: Irland

Sprache: Englisch

Quelle: HPRA (Health Products Regulatory Authority)

Kaufe es jetzt

Fachinformation Fachinformation (SPC)
12-06-2017
DSU DSU (DSU)
07-07-2023

Wirkstoff:

Butorphanol tartrate

Verfügbar ab:

aniMedica GmbH

ATC-Code:

QN02AF01

INN (Internationale Bezeichnung):

Butorphanol tartrate

Dosierung:

4 milligram(s)/millilitre

Darreichungsform:

Solution for injection

Verschreibungstyp:

POM: Prescription Only Medicine as defined in relevant national legislation

Therapiegruppe:

Cats, Dogs

Therapiebereich:

butorphanol

Anwendungsgebiete:

Neurological Preparations

Berechtigungsstatus:

Authorised

Berechtigungsdatum:

2009-12-18

Fachinformation

                                SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Morphasol 4 mg/ml solution for injection for dogs and cats.
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each ml contains:
Active substance
Butorphanol
4 mg
(as Butorphanol tartrate 5.83 mg)
Excipients
Benzethonium chloride
0.1 mg
For the full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Solution for Injection.
A clear, colourless solution.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Dogs and cats.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
DOGS:
As an analgesic: for the relief of mild to moderate visceral pain.
As a sedative: in combination with medetomidine.
CATS:
As an analgesic: for the relief of mild to moderate visceral pain.
4.3 CONTRAINDICATIONS
Do not use in case of known hypersensitivity to the active substance
or to any of the excipients in the product.
Do not use in animals with known or suspected liver or kidney disease.
Use of butorphanol is contraindicated in case of cerebral injury or
organic brain lesions and in animals with obstructive
respiratory diseases, heart dysfunction or spastic conditions.
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
_D_
_a_
_t_
_e_
_ _
_P_
_r_
_i_
_n_
_t_
_e_
_d_
_ _
_1_
_9_
_/_
_1_
_2_
_/_
_2_
_0_
_1_
_4_
_C_
_R_
_N_
_ _
_7_
_0_
_1_
_9_
_4_
_9_
_7_
_p_
_a_
_g_
_e_
_ _
_n_
_u_
_m_
_b_
_e_
_r_
_:_
_ _
_1_
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
Butorphanol is intended for use where short (dog) and short to medium
(cat) analgesia is required. For information on
the duration of analgesi
                                
                                Lesen Sie das vollständige Dokument
                                
                            

Suchen Sie nach Benachrichtigungen zu diesem Produkt